

Cat No. 13-D24

Sorafenib




5mg

For research purposes only

Sorafenib, also known as Nexavar, is a small molecule inhibitor of several tyrosine protein kinases, VEGFR 2 & 3 as well as PDGFR, and RAF/MEK/ERK cascade inhibitor. It also inhibits c-Kit, the ligand for Stem cell factor. It does not significantly inhibit MEK-1 or ERK-1 activity. It interacts in combination with the proteasome inhibitor bortezomib to induce apoptosis in a broad spectrum of neoplastic cell lines.

## TECHNICAL INFORMATION



## STORAGE AND HANDLING

**Storage:** Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

**Stability:** Stock solutions stable at -20°C for up to 2 years.

**Shipping Conditions:** Shipped at room temperature.

## PRODUCT USE

Soluble in DMSO.

**Other Names:** 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamine

**Chemical Formula:** C<sub>12</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub>

**CAS Number:** 284461-73-0

**PubChem Substance ID:** 216239

**Molecular Weight:** 464.82

**Purity:** >99%

**Appearance:** Light yellow solid

**Solubility:** DMSO

**IC<sub>50</sub> :** 6nM

## REFERENCES

1. Bruix, J., et al. (2012). Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Subanalyses of a Phase III Trial. *J Hepatol.* 48:1452-65.
2. Gulhati, P., et al. (2012). Sorafenib Enhances the Therapeutic Efficacy of Rapamycin in Colorectal Cancers Harboring Oncogenic Kras and PIK3CA. *Carcinogenesis.* 859:323-6556.
3. Zauli, G., et al. (2012). The Sorafenib plus Nutlin-3 Combination Promotes Synergistic Cytotoxicity in Acute Myeloid Leukemic Cells Irrespective of the FLT3 and p53 Status. *Haematologica.* 10:3324.